Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bedside Measurements of a Novel Biomarker SPLA2-IIA as a Marker of an Inflammatory Response and Predictor of Sepsis in Patients Meeting SIRS or qSOFA Criteria: a Pilot Study

NCT03953404 is registered in ClinicalTrials.gov with St. Luke's Hospital, Pennsylvania as lead sponsor.

NCT NCT03953404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03953404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bedside Measurements of a Novel Biomarker SPLA2-IIA as a Marker of an Inflammatory Response and Predictor of Sepsis in Patients Meeting SIRS or qSOFA Criteria: a Pilot Study
Lead sponsor
St. Luke's Hospital, Pennsylvania
Phase
Observational
Overall status
Unknown status
Start date
May 14, 2019
Completion date
April 30, 2022
Enrollment
450 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis